News
-
Skyepharma has announced that Mundipharma has launched the Flutiform fluticasone/formoterol MDI for the treatment of asthma in Spain, triggering a milestone payment of €2.0 million. In addition, Mundipharma marketing partner Zambon Italia has now launched… Read more . . .
-
According to Avanir Pharmaceuticals, it has received a Complete Response Letter (CRL) from the FDA regarding its New Drug Application (NDA) for AVP-825 intranasal sumatriptan for the treatment of migraine. The company had recently warned… Read more . . .
-
Respiratory drug developer Verona Pharma has named former Galenica CEO David Ebsworth as Non-Executive Chairman of the Board of Directors. Ebsworth succeeds Clive Page, who founded the company in 2006. The company’s lead product, RPL554,… Read more . . .
-
According to Bayer, its Amikacin Inhale inhalation solution and its ciprofloxacin DPI have both been granted qualified infectious disease product (QIDP) designation by the FDA. Both products are currently in Phase 3 development. Bayer HealthCare… Read more . . .
-
Milestone Pharmaceuticals has announced that a Phase 1 clinical trial of an intranasal formulation of its MSP-2017 calcium channel antagonist for possible treatment of paroxysmal supraventricular tachycardia (PSVT) showed that the drug has a rapid… Read more . . .
-
Endo International has acquired exclusive US and Mexican rights to Trimel BioPharma’s Natesto testosterone nasal gel, which was approved by the the FDA in May 2014 as a replacement treatment for men with low levels… Read more . . .
-
According to AstraZeneca, the European Commission has approved the Duaklir Genuair aclidinium bromide/formoterol fumarate DPI for the treatment of COPD. The EMA’s Committee for Medicinal Products for Human Use (CHMP) recommended approval of the product… Read more . . .
-
According to Sandoz, Ireland and the Czech Republic have approved marketing applications for the AirFluSal Forspiro salmeterol/fluticasone DPI in 50-250 and 50-500 µg dosage forms for the treatment of asthma and/or COPD. The Czech approval… Read more . . .
-
GSK Australia has announced that it plans to invest AUD31 million in blow-fill-seal equipment for the manufacture of Venolin salbutamol nebules at its facility in Boronia, a suburb of Melbourne. The company cited increasing demand… Read more . . .
-
CDMO Catalent has announced its acquisition of particle size reduction specialist Micron Technologies, which offers micronization, milling, and particle characterization services for pharmaceutical products, including inhalation powders. Catalent notes that it offers development through to… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA